Liver cancer is a common and aggressive malignancy, but available treatment approaches remain suboptimal. Cancer targeting Gene-Viro-Therapy (CTGVT) has shown excellent anti-tumor effects in a preclinical study. CTGVT takes advantage of both gene therapy and virotherapy by incorporating an anti-tumor gene into an oncolytic virus vector. Potent anti-tumor activity is achieved by virus replication and exogenous expression of the anti-tumor gene. A dual-regulated oncolytic adenoviral vector designated AdÁAFPÁE1AÁE1B (D55) (AdÁAFPÁD55 for short thereafter) was constructed by replacing the native viral E1A promoter with the simian virus 40 enhancer/a-fetoprotein (AFP) composite promoter (AFPep) based on an E1B-55K-deleted construct, ZD55. AdÁAFPÁD55 showed specific replication and cytotoxicity in AFP-positive hepatoma cells. It also showed enhanced safety in normal cells when compared with the mono-regulated vector ZD55. To improve the anti-hepatoma activities of the virus, the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene was introduced into AdÁAFPÁD55. AdÁAFPÁD55-TRAIL exhibited remarkable anti-tumor activities in vitro and in vivo. Treatment with AdÁAFPÁD55-TRAIL can induce both autophagy owing to the AdÁAFPÁD55 vector and caspase-dependent apoptosis owing to the TRAIL protein. Therefore, AdÁAFPÁD55-TRAIL could be a potential anti-hepatoma agent with anti-tumor activities due to AFP-specific replication and TRAIL-induced apoptosis.
INTRODUCTION
Although major progress has been made in the field of cancer therapy in the past decades, liver cancer remains one of the most refractory malignancies. According to the SEER (Surveillance, Epidemiology and End Results) Cancer Statistics Review 1975-2006 of the USA National Cancer Institute, the 5-year relative survival rate of patients with primary cancer originating from the liver and intrahepatic bile duct was 13.0% from 1999 to 2005 in the United States, which was second only to that of pancreatic cancer patients (5.7%). Hepatocellular carcinoma (HCC), which is the most common type of human liver cancer and the fifth most frequent neoplasm worldwide, represents the third leading cause of cancer-related death. 1 Novel therapeutic methods with high effectiveness and safety are urgently needed.
The Cancer targeting Gene-Viro-Therapy (CTGVT) approach developed by our laboratory is one of the most promising strategies for the treatment of cancer. 2 It combines gene therapy and virotherapy by utilizing an oncolytic adenoviral vector containing an anti-tumor gene. It has greater anti-tumor effects than gene therapy or virotherapy alone. Different strategies were applied to construct the oncolytic virus. The ZD55 vector based on the deletion of the E1B-55K gene was used first in our laboratory. 3 The selective replication of ONYX-015 (similar to ZD55) in cancer cells was first thought to be dependent on P53 deficiency. 4 In 2004, O'Shea et al. 5 attributed ONYX-015's cancerspecific replication to the late viral RNA export ability of E1B 55K. However, ZD55 is a mono-regulated oncolytic vector without the ability to target a specific cancer and has some liver toxicity. 6 To achieve liver cancer targeting and improved safety, a dual-regulated oncolytic adenovirus can be developed by using a liver cancer-specific promoter to drive expression of the replication-essential gene E1A in the E1B-55K-deleted construct. a-Fetoprotein (AFP) is preferentially expressed in over 70% of human liver cancer patients through transcriptional activation. 7, 8 Therefore, the AFP promoter is a good candidate for this purpose. Some dual-regulated oncolytic adenoviral vectors targeting HCC have been explored, including YKL-1001 and AdAFPep/Rep. 9, 10 In AdÁAFPÁE1AÁE1B (D55) (AdÁAFPÁD55 for short thereafter), which is used in this study, E1A expression was under the control of the AFPep composite promoter within the E1B-55K-deleted construct ZD55.
The anti-tumor activities of adenovirus have been widely studied, but the mechanism by which adenovirus induces cancer cell death remains elusive. In 2004, Abou El Hassan et al. 11 reported that conditionally replicating adenoviruses killed tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. More recently, this kind of cell death was identified as autophagic cell death or programmed cell death II. [12] [13] [14] The oncolytic virus has limited anti-tumor activities, but it can target and replicate several hundred-to several thousand-fold in cancer cells. If we insert a therapeutic gene into a replicationcompetent oncolytic viral vector, the gene copy number can increase by several hundred-to several thousand-fold. Many members of our laboratory have shown the strong anti-tumor effect of the CTGVT strategy. 3, 15, 16 In this study, the tumor necrosis factor-related apoptosisinducing ligand (TRAIL) gene was incorporated into the oncolytic adenoviral vector AdÁAFPÁD55. TRAIL was first identified and cloned by Wiley et al. in 1995. 17 Its receptors and signaling-transduction pathways have been extensively studied in the past decade. 18 As TRAIL can induce apoptosis in many types of malignancy without severe damage to normal cells when incorporated into the oncolytic virus, it has been widely used in the field of cancer gene therapy. 19 The bystander effect was also observed for the TRAIL-induced antitumor activities, although the underlying mechanisms responsible for this event are not yet clear. [20] [21] [22] RESULTS Construction and characterization of AFP-targeting oncolytic adenoviruses AFP secretion was assayed in different hepatoma cell lines. As shown in Table 1 , AFP secretion in conditional medium was highest for the HepG2 cell line, up to 1174 ± 17.33 ng ml À1 . The HuH-7 and PLC/ PRF/5 cell lines secreted AFP at moderate levels of 424.87 ± 20.36 and 315.20±2.40 ng ml À1 , respectively. The secretion of AFP by other hepatoma cell lines was low or undetectable. Transcriptional activity of the AFPep composite promoter was measured in different cell lines by use of the luciferase assay. The transcriptional activity of the AFPep composite promoter in different cell lines was consistent with the observed secretion levels of AFP and addition of the simian virus 40 (SV40) enhancer did not alter specificity of the AFP promoter ( Figure 1a) . It is worth noting that the AFPep composite promoter showed very high transcriptional activity in HuH-7 cells, exceeding that of the pGL3-Control. By contrast, transcriptional activity of the AFPep composite promoter was almost undetectable in the immortalized epithelial cell line BEAS-2B. Transcriptional activity could not be measured in the HepG2 and PLC/PRF/5 cell lines owing to their low transfection efficiency. Cancer targeting Gene-Viro-Therapy of hepatoma X Cao et al
The oncolytic adenoviruses constructed in this work are illustrated in Figure 1b . To characterize these viruses, the AFP-positive cell line HuH-7 was infected with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL. E1A expression was assayed by western blot (Figure 1c ) and the TRAIL concentration in the conditional medium was measured by enzymelinked immunosorbent assay (Figure 1d ).
Selective cytotoxicity of Ad . AFP . D55 and Ad . AFP . D55-TRAIL in AFP-positive hepatoma cell lines and improved safety in the normal cell line To test infectability of the new constructs in various cell lines, all cell lines were infected with AdÁAFPÁD55 harboring enhanced green fluorescent protein (EGFP) genes (that is, AdÁAFPÁD55-EGFP) at a multiplicity of infection (MOI) as indicated. All cell lines can be infected by AdÁAFPÁD55-EGFP, although the infection efficiencies may vary between different cell lines (Supplementary Figure 1) . The HuH-7 and BEL-7404 cell lines showed the highest infection efficiencies, with 76.01 and 78.79% GFP-positive cells, respectively, infected at an MOI of 10. The differences in replication capabilities between the monoregulated oncolytic adenovirus ZD55 and the dual-regulated oncolytic adenoviruses AdÁAFPÁD55 and AdÁAFPÁD55-TRAIL in the various cell lines were assayed using the standard tissue culture infectious dose 50 method. AdÁAFPÁD55 and AdÁAFPÁD55-TRAIL can selectively replicate in AFP-positive hepatoma cells, and their replication abilities were strongly attenuated in AFP-negative cells, including the HCC cell line BEL-7404. However, the mono-regulated oncolytic adenovirus ZD55 can replicate efficiently in all cancer cells (Figure 2a) .
The dual-regulated oncolytic adenoviral vector AdÁAFPÁD55 can induce cytopathic effects as efficiently as the mono-regulated oncolytic adenoviral vector ZD55 in AFP-positive hepatoma cell lines (HuH-7, HepG2 and PLC/PRF/5), whereas its oncolytic ability was more strongly attenuated in AFP-negative cancer cell lines (Bcap-37, SW-620 and BEL-7404) (Figure 2b ). The safety of AdÁAFPÁD55 in the immortalized epithelial cell line BEAS-2B was also improved compared with ZD55; it caused little damage to BEAS-2B cells even at an MOI of 200 (Figure 2c ). The safety of AdÁAFPÁD55 for normal cells was further supported by the result from normal fibroblast cell line MRC-5 and HFL1 (Supplementary Figure 3) . What is more, the enhanced safety of AdÁAFPÁD55 compared with ZD55 was also evaluated in vivo by intravenous injection in nude mice. The serum level of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in AdÁAFPÁD55-treated mice were reduced compared with the ZD55-treated ones (Po0.05) (Figure 2d ). It indicated that AdÁAFPÁD55 was safer and better tolerated than ZD55 when delivered systematically in nude mice.
The pro-apoptotic TRAIL gene was introduced into the AFPtargeting oncolytic adenoviral vector to form the dual-regulated gene-viral system, AdÁAFPÁD55-TRAIL. AdÁAFPÁD55-TRAIL showed Cancer targeting Gene-Viro-Therapy of hepatoma X Cao et al enhanced cytotoxicity compared with AdÁAFPÁD55 in the AFP-positive hepatoma cell lines (HuH-7 and HepG2), which was shown by crystal violet staining and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Figures 3a and b) . However, no severe side effect was induced by AdÁAFPÁD55 and AdÁAFPÁD55-TRAIL infection at an MOI of 10 in the immortalized epithelial cell line BEAS-2B (Figures 3a and b) and normal fibroblast cell line MRC-5 or HFL1 (Supplementary Figure 4) assayed by the same methods. It is intriguing that AdÁAFPÁD55 and AdÁAFPÁD55-TRAIL also showed some cell-killing effect in AFP-negative hepatoma cell lines BEL-7404 at an MOI of 10, although not effective as that in HuH-7 and HepG2 (Supplementary Figure 2) .
Ad . AFP . D55 and Ad . AFP . D55-TRAIL infection may cause autophagy Infection with ZD55 or AdÁAFPÁD55 at an MOI of 10 for 48 h enhanced the intracellular ATP level in HuH-7 cells ( Figure 4A) . A decrease in intracellular ATP levels is frequently considered a biochemical marker of necrosis. A drop in the ATP level also indicates decreased or impaired mitochondrial function, and it is often associated with mitochondrial membrane potential dissipation during apoptosis. Our results suggest that neither necrosis nor apoptosis is the principal cause of cell death induced by ZD55 or AdÁAFPÁD55.
To investigate the mechanism of cell death induced by AdÁAFPÁD55 infection, a plasmid encoding the EGFP-microtubule-associated protein light chain 3 (LC3) fusion protein was transfected into HuH-7 cells before adenoviral infection. LC3 is first cleaved at the carboxy terminus immediately following synthesis to yield a cytosolic form LC3-I. During autophagy, LC3-I is converted to LC3-II through lipidation by an ubiquitin-like system that allows for LC3 to become associated with autophagic vesicles. The distribution of EGFP-LC3 from diffused (LC3-I) in the cytosol to punctuate (LC3-II) indicates that autophagy occurs. EGFP-LC3 diffused into the cytosol in the mock group, whereas numerous punctate structures expressing EGFP were easily seen after infection of HuH-7 cells with ZD55, AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL ( Figure 4B ). To quantify the cell population that underwent autophagy after different treatments, cells with more than five EGFP-LC3-positive punctae (each greater than 1 mm in diameter) were counted using the Operetta Compact High Content Screening System. In AFP-positive HuH-7 cells, AdÁAFPÁD55 and AdÁAFPÁD55-TRAIL infection caused an apparent increase in EGFP-dotted cells compared with that of mock treatment (Po0.01; t-test), up to 12.11 and 20.46%, respectively. The presence of these structures was inhibited by the addition of 3-methylademine, a widely used autophagy inhibitor. There were no significant differences in the immortalized epithelial BEAS-2B cell line among the different treatments ( Figure 4C ).
Ultrastructures of HuH-7 cells under different treatments were observed by transmission electron microscopy. Both AdÁAFPÁD55-and AdÁAFPÁD55-TRAIL-infected cells displayed a large quantity of vacuolated structures in the cytoplasm, which is a hallmark of autophagy. Furthermore, apoptotic bodies were observed around the AdÁAFPÁD55-TRAIL-infected HuH-7 cells ( Figure 4D , panel a). To validate the occurrence of autophagy in a more convincing manner, the translocation of LC3 to autophagosomes was shown by postembedding immunogold staining ( Figure 4D , panel b). Briefly, 10-nm colloidal gold particles were located on the membrane of autophagosomes after infection with the oncolytic adenovirus, whereas cytoplasmic localization was observed in the mock-treated cells.
The conversion of LC3-I to LC3-II with or without chloroquine incubation was monitored by western blotting. As endogenous LC3-II is considerably degraded by lysosomal hydrolases after the formation of autolysosomes, the amount of LC3-II seemed to be only moderately upregulated after infection with either AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL without chloroquine incubation. Chloroquine increases the pH of lysosome, thereby preventing the activity of lysosomal acid proteases and causing autophagosomes to accumulate. Strikingly, LC3-II accumulated at an apparently high level after both adenoviral infection at an MOI of 10 for 4 days compared with mockinfected group with chloroquine incubation for 6 h ( Figure 4E ). Autophagy induced by oncolytic adenovirus infection was also shown by the degradation of p62/SQTM1, which is the substrate of autophagy process ( Figure 4E ).
Ad . AFP . D55-TRAIL-induced apoptosis of HuH-7 cells After different treatments, the nuclear morphology of the HuH-7 and BEAS-2B cell lines was observed under a confocal microscope after Hoechst 33258 staining. The infection of HuH-7 cells with AdÁAFPÁ D55-TRAIL can induce nuclear fragmentation and chromatin condensation, which are characteristic of apoptosis. However, mock infection and infection with AdÁAFPÁD55 did not cause abnormal nuclear morphology of the HuH-7 cells. Infection with either AdÁAFPÁ D55 or AdÁAFPÁD55-TRAIL did not cause damage to the immortalized epithelial cell line BEAS-2B (Figure 5a ). Similar results were confirmed by the DNA fragmentation assay. The DNA ladder was clearly seen in AdÁAFPÁD55-TRAIL-treated HuH-7 cells (Figure 5b ).
To quantitate the proportion of cells that underwent apoptosis, samples of HuH-7 hepatoma cells and BEAS-2B immortalized epithelial cells under different treatments were stained by propidium iodide and analyzed by flow cytometry. The number of HuH-7 cells in the sub-G1 phase was elevated after AdÁAFPÁD55-TRAIL infection compared with HuH-7 cells after mock and AdÁAFPÁD55 infection. No significant differences were seen in the immortalized epithelial cell line BEAS-2B after each treatment (Figure 5c ). To address whether the apoptosis induced by AdÁAFPÁD55-TRAIL was caspase dependent, the expression of TRAIL and activated caspase-3 in the HuH-7 cell line after adenoviral infection was analyzed by immunofluorescence. Cleaved caspase-3 was expressed in the AdÁAFPÁD55-TRAIL treatment group, and it seemed to correlate with TRAIL expression as neither infection with AdÁAFPÁD55 nor mock infection induced caspase-3 activation (Figure 5d ). Expression of the key proteins involved in the extrinsic and intrinsic apoptosis pathways was evaluated by western blotting. The expression levels of procaspase-3, procaspase-8 and procaspase-9 were reduced, and cleaved caspase-3, cleaved caspase-8 and cleaved caspase-9 was detected after AdÁAFPÁD55-TRAIL infection at an MOI of 10 for 3 or 4 days. The poly-(ADP-ribose) polymerase substrate of caspase-3 was also cleaved with AdÁAFPÁD55-TRAIL treatment (Figure 5e ). Cytoplasmic and mitochondrial proteins were extracted from the HuH-7 cell line after different treatments. Translocation of cytochrome c from the mitochondria to the cytoplasm after AdÁAFPÁD55-TRAIL infection of HuH-7 cells was validated by western blotting (Figure 5f ). The mitochondrial outer membrane protein voltage-dependent anion channel was applied to exclude mitochondria-derived contaminant in the cytosol part. The extrinsic and intrinsic apoptosis pathways were activated after AdÁAFPÁD55-TRAIL infection of the HuH-7 cell line.
Anti-hepatoma effect of Ad . AFP . D55-TRAIL in nude mice A hepatoma xenograft model was established by inoculating AFPpositive HuH-7 cells into the right back of nude mice. When tumor volume reached 80-150 mm 3 , phosphate-buffered saline (PBS), AdÁAFPÁD55 and AdÁAFPÁD55-TRAIL were administered by intratumoral injection in each group. Tumor volumes were monitored weekly after the first injection. The tumors grew rapidly and exceeded a mean of 1200 mm 3 within a month in the PBS group. Tumor growth in the AdÁAFPÁD55 and AdÁAFPÁD55-TRAIL groups was significantly inhibited. It is worth noting that nearly 74% of the tumor burden was inhibited in the AdÁAFPÁD55-TRAIL group compared with the PBS group at the end of the fourth week, with a mean volume of 328 mm 3 (Figure 6a ). The serum liver levels of ALT, AST and alkaline phosphatase (ALP) were assayed in each group (Figure 6b ). There were no significant differences between each treatment, indicating that the intratumoral administration of AdÁAFPÁD55 and AdÁAFPÁD55-TRAIL caused little hepatotoxicity.
To confirm that the tumoricidal activities were mediated by the dual-regulated oncolytic virus, expression of the viral proteins E1A and Hexon and the therapeutic gene TRAIL were measured by immunohistochemistry in tumor specimens harvested at 7 days after the first injection of virus. The expression of E1A and Hexon can be observed in both AdÁAFPÁD55-and AdÁAFPÁD55-TRAILtreated samples, and expression of TRAIL was only seen in the AdÁAFPÁD55-TRAIL-treated sample (Figure 6c) . Furthermore, the viral replication kinetics of AdÁAFPÁD55-TRAIL in the tumor were measured by TaqMan real-time PCR using the adenoviral shuttle plasmid pXC1 to generate the standard curve (Figure 6d, left panel) . Viral replication of AdÁAFPÁD55-TRAIL peaked at 5 days after the first injection, with a mean of 4.52Â10 6 copies per nanogram of total DNA (Figure 6d, right panel) . Similar replication kinetics were observed for AdÁAFPÁD55 (data not shown).
Ad . AFP . D55-TRAIL induced autophagy and apoptosis in vivo To validate the mechanisms of cell death induced by AdÁAFPÁD55-TRAIL in vivo, autophagy and apoptosis were assayed in HuH-7 tumor specimens using different methods. Hexon and LC3 proteins in the ultrathin sections of HuH-7 tumors were stained by the postembedding immunogold cytochemical reaction. As shown in Figure 7a , the 10-nm colloidal gold particles staining LC3 were located in the membrane of autophagosomes in the AdÁAFPÁD55-and AdÁAFPÁD55-TRAIL-treated samples, whereas their distribution was dispersed throughout the cytosol in the PBS-treated sample. The phenomenon mentioned above indicates that infection with the oncolytic adenovirus might cause autophagic cell death in vivo. Cancer targeting Gene-Viro-Therapy of hepatoma X Cao et al
The terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) assay was used to detect apoptosis in paraffin sections of HuH-7 tumors in situ. A large area of TUNEL-positive cells was only seen in the AdÁAFPÁD55-TRAILtreated samples (Figure 7b ). Expression levels of TRAIL and cleaved caspase-3 were measured by immunofluorescence. As shown in Figure 7c , the apoptosis induced by AdÁAFPÁD55-TRAIL in vivo was caspase-3 dependent and correlated with the expression of TRAIL.
DISCUSSION
To achieve targeting of HCC and improved safety in normal cells, a dual-regulated oncolytic vector designated as AdÁAFPÁD55 and based on the ZD55 vector was constructed using the AFPep composite promoter to drive E1A expression. The AFPep composite promoter consists of a 0.3-kb AFP promoter and a 235-bp SV40 enhancer. The 0.3-kb AFP promoter contains a glucocorticoid response element and two binding sites for hepatocyte nuclear factor-1, a hepatocyte-specific transcriptional factor. It also contains a TATA box, but it lacks the typical CCAAT sequence. Although a previous study showed that the 0.3-kb AFP promoter had sufficient activity to stimulate the transcription of downstream genes, its efficiency was limited. 23, 24 For this reason, the AFP enhancer is often inserted upstream of the promoter to increase its activity. However, the AFP enhancer spans a long sequence. The AFP enhancer utilized by Minoru et al. 10 was 0.7 kb. To save space for the exogenous gene expression cassette, the shorter SV40 enhancer was used. The SV40 enhancer is comprised of a 72-base pair repeat. Its efficiency at increasing promoter activity was previously shown by many groups. 25, 26 Introduction of the SV40 enhancer upstream of the 0.3-kb AFP promoter did not change the transcriptional specificity of the AFP promoter (Figure 1a) . Transcriptional activities of the AFPep composite promoter may not be as powerful as the original E1A promoter of the wild-type adenovirus as the replication ability of AdÁAFPÁD55 was weaker than that of ZD55, even in AFP-positive cells (Figure 2a) . However, the cytotoxicity of AdÁAFPÁD55 in AFP-positive cells was comparable to that of ZD55 (Figure 2b) .
Obvious autophagy was observed during both AdÁAFPÁD55 and AdÁAFPÁD55-TRAIL infection and was illustrated by EGFP-LC3 translocation, autophagosome formation and LC3-II induction ( Figures 4B-E) . Autophagy is a conserved catabolic process for the autophagosomic-lysosomal degradation of long-lived proteins, organelles and bulk cytoplasm. 27, 28 Although autophagy can act to promote cell survival during starvation, excessive autophagy may result in type II programmed cell death. 29, 30 Jiang et al. 31 speculated that autophagy may facilitate material recycling, energy production and viral release during adenovirus infection. Our data support this hypothesis to some extent. Elevated intracellular ATP levels were observed during oncolytic adenoviral infection ( Figure 4A ), which suggest that adenoviral infection may increase ATP levels to provide sufficient energy for the increased anabolism in infected cells. Cytoplasmic structure and nuclear and cellular membranes were destroyed late in the adenoviral infection cycle by excessive autophagy (Figure 4D ), which facilitated the release of virions.
Introduction of the TRAIL gene in the dual-regulated oncolytic vector AdÁAFPÁD55 resulted in the induction of apoptosis. Extrinsic and intrinsic apoptotic pathways were involved in cell death by the AdÁAFPÁD55-TRAIL virus as shown by western blotting (Figure 5e) . Interestingly, the percentage of autophagy is higher in TRAIL-expressing cells than that in AdÁAFPÁD55-infected cells as shown in Figure 4C . The roles of TRAIL in autophagy have been investigated extensively, but still elusive. TRAIL-induced autophagy was found in lumen formation of MCF-10A human mammary epithelial cells in vitro, 32 apoptosis-defective tumor cells 33 and untransformed human epithelial cells. 34 Activation of TRAIL receptor 2 by a human Cancer targeting Gene-Viro-Therapy of hepatoma X Cao et al single-chain fragment variable antibody HW1 can induce autophagic cell death in both TRAIL-sensitive and -resistant cancer cells. 35 Although the concurrence of autophagic and apoptotic cell death was reported from a combination of adenoviral virotherapy and temozolomide chemotherapy in malignant glioma, 36 the results presented here are the first to show that these two distinct programmed cell death pathways can be simultaneously induced by a single geneviral agent in hepatoma.
One important concern of hepatoma treatment is the resistance of HCC to drugs, including TRAIL. Previous reports showed that E1A expression enhanced TRAIL sensitivity in human cancer cells and normal cell lines. 37, 38 Hence, incorporation of TRAIL gene into oncolytic adenovirus with E1A expression may make some TRAILresistant cancer cells sensitive to our gene-viral agent. As the E1A expression was under the control of AFPep composite promoter in AdÁAFPÁD55, E1A expression was dependent on AFP status of cell line Tumor sections derived from the in vivo study were subjected to an in situ cell apoptosis detection kit to detect apoptotic cells. The TUNEL-positive cells were only observed in the AdÁAFPÁD55-TRAIL-treated group. Scale bar¼50 mm. (c) Tumor sections derived from the in vivo study were subjected to an immunofluorescence assay to evaluate the expression of TRAIL and cleaved caspase-3. Scale bar¼22 mm.
Cancer targeting Gene-Viro-Therapy of hepatoma X Cao et al infected and could not express in normal cell line, leaving AdÁAFPÁD55-TRAIL-infected normal cells spared. This explanation was supported by cytotoxic effect of AdÁAFPÁD55-TRAIL in TRAILresistant cell line HepG2 and immortalized epithelial cell line BEAS-2B (Figure 3) . Although the volume of HuH-7 xenograft tumor was diminished by AdÁAFPÁD55-TRAIL in this study, it was not eliminated. Our previous work verified that the entire inoculated tumor could be completely eradicated by utilization of two genes with compensatory or synergetic effects, which is the basis of the Cancer Targeting Dual Gene-Viro-Therapy strategy. [39] [40] [41] As SOCS3 is deficient in HCC and may sensitize human hepatoma cells to TRAILmediated apoptosis, 42, 43 AdÁAFPÁD55 armed with the SOCS3 gene was constructed. The anti-hepatoma activities of AdÁAFPÁD55-SOCS3 and AdÁAFPÁD55-TRAIL co-treatment are currently being assessed.
MATERIALS AND METHODS

Cell culture
The HepG2, Hep3B, BEL7404, BEL-7402, SMMC-7721 (human HCC), Bcap-37 (human breast cancer), SW620 (human colorectal cancer), MRC-5 and HFL1 (normal lung fibroblast cell) cell lines were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). The human HCC cell lines HuH-7 and HuH-6 were obtained from the RIKEN Cell Bank (Ibaraki, Japan). The highly spontaneous metastatic human HCC cell line HCCLM6 was obtained from the Liver Cancer Institute, Zhongshan Hospital, Fudan University (Shanghai, China). The human hepatoma cell line PLC/PRF/5 was kindly provided by Dr Qi-Jun Qian from Second Military Medical University (Shanghai, China). Immortalized epithelial cell line BEAS-2B, which was isolated from normal human bronchial epithelium obtained from autopsy of non-cancerous individuals, was a kind gift from Professor Hong-Bin Ji's lab in Shang Institute of Biochemistry and Cell Biology. The HEK293 cell line was purchased from Microbix Biosystems Inc. (Toronto, Ontario, Canada). Cell lines were maintained in Dulbecco's modified Eagle's medium (GIBCO BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (GIBCO BRL). All cell lines were incubated at 37 1C in a humidified air atmosphere with 5% CO 2 .
AFP measurement
Cells were seeded in 24-well plates and cultured at 37 1C for 24 h. The cultured medium was then replaced by fresh medium without fetal bovine serum. After 24 h of cultivation, AFP concentrations in the media were measured by the radioimmunity method at Zhongshan Hospital, Fudan University (Shanghai, China).
Reporter gene assay to measure the transcriptional activity of the AFPep composite promoter
The plasmid pDRIVE03-SV40enh/AFP(h) v04 containing the SV40 enhancer and human AFP promoter sequence was purchased from InvivoGen Inc. (San Diego, CA, USA). Luciferase reporter plasmids pGL3-Basic (promoter-free) and pGL3-Control (with SV40 promoter/enhancer) were purchased from Promega Corp. (Madison, WI, USA). The plasmid pGL3-AFPep was constructed by inserting the AFPep composite promoter sequence into the pGL3-Basic plasmid. To measure the transcriptional activity of the AFPep composite promoter in different cell lines, cells were seeded in 24-well plates and cotransfected with 0.8 mg of reporter plasmid and 0.08 mg of internal control plasmid pCMV-b-galactosidase encoding b-galactosidase using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). At 48 hours post-transfection, cells were harvested and the firefly luciferase and b-galactosidase activities were assayed using the Luciferase reporter assay system (Promega) and the b-galactosidase assay kit (Beyotime, Haimen, China), respectively.
Construction of the oncolytic adenoviral shuttle vectors
The adenoviral shuttle plasmids pZXC2 (ref. 44 ) and pZD55 (ref. 3) were previously constructed and preserved in our laboratory. The two plasmids mentioned above were digested with EcoRI and XbaI, respectively. The smaller fragment of the former (1.5 kb) and larger fragment of the latter (7.3 kb) were ligated by treatment with T4 DNA ligase (TaKaRa, Shiga, Japan) to form a novel shuttle plasmid designated pZXC2-ZD55, which lacks the E1A promoter and E1B-55K. To obtain the AFPep composite promoter, PCR was performed with high-fidelity polymerase KOD-plus (ToYoBo, Osaka, Japan) and the plasmid pDRIVE03-SV40enh/AFP(h) v04 was used as a template. The primers used for amplification were as follows: sense primer, 5¢-GCACTCGAGGGCCT GAAATAACCTCTG-3¢; antisense primer, 5¢-GACTACGTATGTTATTGGCAGT GGTGG-3¢. The XhoI and SnaBI recognition sites are underlined. The PCR product was digested with XhoI and SnaBI and ligated into the XhoI/SnaBI site of pZXC2-ZD55 to form plasmid pAFP-D55. The TRAIL expression cassette (with hCMV promoter and SV40 polyadenylation signal) was released from the previously constructed plasmid pCA13-TRAIL by digestion with BglII. It was inserted into the BglII site of pAFP-D55 to generate the recombinant plasmid named pAFP-D55-TRAIL. The plasmid pAFP-D55-EGFP was constructed by the same method.
Generation, purification and titration of recombinant adenovirus
Oncolytic adenoviruses (AdÁAFPÁD55, AdÁAFPÁD55-TRAIL and AdÁAFPÁD55-EGFP) were constructed by standard homologous recombination techniques using the adenoviral shuttle plasmids (pAFP-D55, pAFP-D55-TRAIL and pAFP-D55-EGFP) and the adenovirus packaging plasmid pBHGE3 (Microbix Biosystems Inc.) in HEK293 cells. One microgram of shuttle plasmid was mixed with 0.5 mg of pBHGE3 and then co-transfected into HEK293 cells (sixwell format) using the Effectene Transfection Reagent (Qiagen, Hilden, Germany). The resultant recombinant adenovirus was isolated from a single plaque and expanded in HEK293 cells. Genomic DNA harvested from the candidate viruses was extracted using the Genomic DNA MiniPreps Kit for Blood (Generay, Shanghai, China) and evaluated by PCR to verify its structure and exclude wild-type adenovirus contamination.
Large-scale purification of adenoviruses was performed by ultracentrifugation with cesium chloride. The titers were determined by plaque assay with HEK293 cells.
Enzyme-linked immunosorbent assay to evaluate TRAIL expression in conditional medium
After AdÁAFPÁD55-TRAIL infection at an MOI of 10, the supernatants of HuH-7 cells were collected from 1 to 6 days post-infection. The expression of TRAIL in cell culture media was measured with a commercial human TRAIL enzymelinked immunosorbent assay kit following the manufacturer's instructions (Bender MedSystems, Vienna, Austria).
Virus progeny production assay
Cells were infected with different viruses at an MOI of 10. After 48 h of infection, the medium and cells were collected and lysed by three freeze-thaw cycles. The products were titrated by the tissue culture infectious dose 50 method using HEK293 cells, and the results were transformed to PFU per cell. These experiments were repeated three times.
Cytopathic assay
Different cell lines were grown to subconfluence and infected with adenoviruses at various MOIs. At 5 days after infection, cells were exposed to 2% crystal violet in 20% methanol for 15 min, washed with distilled water (dH 2 O) and documented in photographs.
Cell viability by the colorimetric MTT assay
Cells were seeded in 96-well plates at a density of 6Â10 3 cells per well. When cells reached subconfluence, they were infected with adenoviruses at the indicated MOI. The colorimetric MTT assay was performed as described previously. 45 The percentage of cell viability was calculated as follows: (mean A 570 of infected cells)/(mean A 570 of uninfected cells)Â100%.
Autophagy assay by EGFP-LC3 translocation
To measure autophagy, HuH-7 cells seeded in 24-well plates were transfected with 0.8 mg pEGFP-LC3 by Lipofectamine 2000 (Invitrogen), followed by mock infection or AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL infection at an MOI of 10 after 6 h oftransfection. At 48 h after post-infection, the cellular localization pattern of EGFP-LC3 was photographed using a Leica TCS SP2 confocal microscope (Leica Microsystems, Wetzlar, Germany). To quantify the percentage of EGFP-LC3-positive cells with EGFP-LC3 punctate dots, HuH-7 or BEAS-2B cells seeded in 96-well plates were treated as above with or without 1 mM 3-methylademine (Merck-Calbiochem, Darmstadt, Germany) pre-treatment before infection. Cells with more than five EGFP-LC3 punctate dots (greater than 1 mm in diameter) were counted using an Operetta Compact High Content Screening System (Perkin-Elmer, Waltham, MA, USA). Four random fields per well were counted in triplicate well per condition per experiment.
Transmission electron microscopy for morphological observation and post-embedding immunogold staining
The ultrastructure of HuH-7 cells after mock infection or infection with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL at an MOI 10 for 3 days was observed by transmission electron microscopy using the standard procedure. For determination of the subcellular localization of LC3, ultrathin sections of HuH-7 cells or tumors were stained by post-embedding immunogold staining using the Leica EM IGL Automated Immunolabeling System (Leica Microsystems). Anti-LC3 antibody was purchased from MBL International Corporation (Nagoya, Japan) and anti-Hexon antibody was obtained from Millipore Corporation (Billerica, MA, USA). Colloidal gold-labeled goat anti-rabbit immunoglobulin (Ig)G (10 nm) (Sigma, St Louis, MO, USA) was applied to detect anti-LC3 antibody and rabbit anti-goat IgG (10 nm) (Sigma) was applied to detect anti-Hexon antibody. Images were obtained with a Jeol JEM-1230 transmission electron microscope (JEOL Ltd, Akishima, Japan).
Hoechst 33258 staining and DNA fragmentation
HuH-7 and BEAS-2B cells were grown on glass coverslips in a six-well plate and treated with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL at an MOI of 10 for 48 h or left untreated (mock). Cells were fixed with 4% paraformaldehyde and stained with 1 mg ml À1 Hoechst 33258 (Molecular Probes, Eugene, OR, USA) for 5 min. Cells were then washed twice with PBS and visualized with a Leica TCS SP2 confocal microscope.
For the DNA fragmentation assay, HuH-7 or BEAS-2B cells were seeded in 10-cm culture dishes (5Â10 6 cells per dish) and infected with the indicated viruses. At 72 h post-infection, genomic DNA was extracted as previously described and separated by electrophoresis through 2% agarose gels. 46 
Cell cycle analysis by flow cytometric analysis
To quantitate apoptosis using flow cytometry, both adherent and floating cells were harvested at 48 h after mock infection or infection with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL at an MOI 10, washed with PBS and fixed in 70% ethanol at 4 1C overnight. Fixed samples were washed again with PBS and incubated at 37 1C with 20 mg ml À1 RNaseA. After 30 min, cells were washed with PBS and stained with 500 ml (50 mg ml À1 ) propidium iodide (Sigma) for 1 h. Cellular DNA distribution was analyzed with a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The cell cycle profile was analyzed using the FlowJo version 5.7.2 software (Tree Star Inc., Ashland, OR, USA).
Indirect immunofluorescence assay
HuH-7 cells were placed overnight in six-well plates on poly-L-lysine-coated glass coverslips. At 48 h post-infection with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL at an MOI 10 or mock treatment, cells were washed twice with PBS, fixed with freshly prepared 4% formaldehyde in PBS and incubated with 0.05% Triton X-100 for 5 min at room temperature. For the in vivo study, tumors were fixed with 4% formaldehyde, embedded in Jung tissue freezing medium (Leica Microsystems) and 10-mm sections were cut. TRAIL (BioVision, Palo Alto, CA, USA) or cleaved caspase-3 (Beyotime) antibody was applied to the cells or tissue sections and detected with a tetramethyl rhodamine isothiocyanate-conjugated goat anti-rabbit IgG (H+L) (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) or a tetramethyl rhodamine isothiocyanate-conjugated rabbit anti-mouse IgG+IgM (H+L) (Jackson ImmunoResearch Laboratories). The samples were viewed and images were obtained with a confocal imaging system (Leica TCS SP2).
Subcellular protein fractionation
HuH-7 cells with total number of 5Â10 7 were mock infected or infected with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL at an MOI of 10 for 3 days. Mitochondrial and cytosolic proteins were prepared with a Mitochondrial Protein Isolation kit (KeyGen, Nanjing, China).
Western blot analysis
For oncolytical adenovirus characterization, HuH-7 cells seeded in six-well plates were mock infected or infected with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL at an MOI of 10 for 1-4 days. For LC3-II and p62 detection, HuH-7 cells seeded in six-well plates were mock infected or infected with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL at an MOI of 10 for 4 days with or without incubation with 50 mM chloroquine (Sigma) for 6 h before sample collection. For detection key proteins involved in apoptotic pathway, HuH-7 cells seeded in six-well plates were mock infected or infected with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL at an MOI 10 for 3 or 4 days. Total proteins from different samples were extracted with cell lysis buffer for western blot and immunoprecipitation analyses (Beyotime) and quantitated using an Enhanced BCA Protein Assay Kit (Beyotime). Western blot analysis was carried out using standard procedures. E1A, cleaved caspase-3, cleaved caspase-8, cleaved caspase-9, glyceraldehyde 3-phosphate dehydrogenase and voltage-dependent anion channel antibodies were purchased from Cell Signaling Inc. (Danvers, MA, USA). Procaspase-3, procaspase-8 and horseradish peroxidase-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The procaspase-9 antibody was manufactured by Thermo Fisher Scientific Inc. (Fremont, CA, USA) and the cytochrome c antibody was purchased from R&D Systems (Minneapolis, MN, USA). LC3 and p62 antibody was purchased from MBL International Corporation (Nagoya, Japan). The expression levels of LC3-II and p62 were quantified by densitometry using the Image J software and expressed relative to glyceraldehyde 3-phosphate dehydrogenase signals.
Animal experiments
Four-week-old female athymic nude mice were purchased from the Shanghai Experimental Animal Center (Shanghai, China). All procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. For the treatment of pre-established tumors, 5Â10 6 HuH-7 cells in 150 ml Dulbecco's modified Eagle's medium were subcutaneously injected into the right back of each mouse. When tumors reached 80-150 mm 3 , mice were randomly divided into three groups (five mice per group). AdÁAFPÁD55, AdÁAFPÁD55-TRAIL (2Â10 9 PFUs per mouse) or PBS was injected into the tumors for 5 consecutive days at 50 ml per injection. Tumor volume (mm 3 ) was measured by a vernier caliper weekly and calculated as (lengthÂwidth 2 )/2.
For the toxicology studies, mice in three groups (n¼4 per group) were treated by the same method as mentioned above. All mice were killed for serum AST, ALT and ALP measurements at 3 days after treatment. The serum levels of AST, ALT and ALP were determined by use of a Hitachi Automatic Analyzer 7080 (Tokoyo, Japan).
Serology assays
To show enhanced safety of AdÁAFPÁD55 over ZD55 in vivo, ZD55, AdÁAFPÁD55 (2Â10 9 PFUs per mouse) or PBS was intravenously injected into nude mice (n¼3 per group) by a single injection of 250 ml. At 24 h postinjection, the serum levels of ALT and AST were determined by automated colorimetric assays with Hitachi Automatic Analyzer 7080.
Adenoviral replication kinetics in vivo as determined by TaqMan real-time PCR
To study viral replication kinetics in vivo, tumors injected with AdÁAFPÁD55 or AdÁAFPÁD55-TRAIL were collected at 5, 10, 15 and 20 days after the first injection and quickly frozen in liquid nitrogen. Total tissue DNA was extracted Cancer targeting Gene-Viro-Therapy of hepatoma X Cao et al using the Genomic DNA MiniPrep Kit for Cells/Tissue (Generay). Viral DNA content was measured by TaqMan real-time PCR as described previously. 47 The primers and probe used for TaqMan real-time PCR are listed below: E1-adenovirus forward, 5¢-GGGTGAGGAGTTTGTGTTAGATTATG-3¢; E1-adenovirus reverse, 5¢-TCCTCCGGTGATAATGACAAGA-3¢; E1-adenovirus probe, TET-5¢-AGCACCCCGGGCACGGTTG-3¢-TAMRA (detecting Ad5 gene E1A). The plasmid pXC1 (Microbix Biosystems Inc.) containing the E1 region of adenovirus was applied to generate the standard curve.
Immunohistochemical analysis
Tumor tissues were fixed in 4% formaldehyde, dehydrated with an ethanol gradient and embedded in paraffin. Tissue sections were dewaxed and rehydrated according to a standard protocol. The sections were washed with PBS, treated with 3% H 2 O 2 and blocked with blocking solution. These steps were followed by overnight incubation with primary antibody at the proper dilution. The following procedures were performed with the rabbit or goat SP (horseradish peroxidase) Staining System (Westang Biotechnology, Shanghai, China) according to the manufacturer's instructions. Hematoxylin was used as a counterstain. All sections were examined with bright field microscopy.
TUNEL assay
Apoptotic cells in tumor tissue sections were assessed using an in situ apoptosis detection kit (KeyGen) according to the manufacturer's instructions. Sections were counterstained with hematoxylin.
Statistical analysis
Statistical significance was assessed with the Student's t-test and one-way analysis of variance by GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA). Results were considered statistically significant when Po0.05.
